About the Company
Neuralstem Inc. is a biotechnology company headquartered in Rockville, Maryland that specializes in developing commercial-scale production of multiple types of central nervous system stem cells. In October 2019 Neuralstem announces that the company has changed its name to Seneca Biopharma, Inc. In April 2021 Seneca Biopharma merged with Leading BioSciences to form the combined company Palisade Bio, Inc.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on PALISADE BIO, INC.
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides ...
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook Nov. 10, 2023 8:05 AM ET Palisade Bio, Inc. (PALI) ...
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides ...
JTC Team, LLC Jenene Thomas 833-475-8247 PALI@jtcir.com Source: Palisade Bio Palisade Bio, Inc. Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share amounts) ...
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide ...
Carlsbad, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic ...
Palisade Bio’s PALI-2108: A Promising New Treatment for Ulcerative Colitis
Palisade Bio, Inc. (($PALI)) announced an update on their ongoing clinical study. Study Overview: Palisade Bio, Inc. has completed a Phase 1 ...
Palisade Bio’s stock more than doubles on news of ... - MarketWatch
Palisade Bio Inc.’s stock PALI more than doubled in price on Wednesday, after the company announced a licensing agreement with privately held Giiant Pharma Inc. Carlsbad, Calif.-based Palisade ...
Palisade Bio, Inc. Appoints Dr. Emil Chuang to Board of ... - Nasdaq
Palisade Bio, Inc. Appoints Dr. Emil Chuang to Board of Directors to Enhance Clinical Strategy for Fibrostenotic Crohn's Disease and Ulcerative Colitis July 09, 2025 — 08:50 am EDT ...
Palisade Bio, Inc. Closes $5 Million Underwritten Public ... - Nasdaq
Palisade Bio closed a $5 million public offering to fund clinical trials and research for autoimmune and inflammatory diseases. Quiver AI Summary Palisade Bio, Inc. has successfully closed an ...
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide ...
– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024 – Inflammatory bowel ...
PALI - Palisade Bio Inc Key Metrics | Morningstar
Review the current Palisade Bio Inc (PALI:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if PALI is the best investment for you.
Similar Companies
Loading the latest forecasts...